PITTSBURGH COMPOUND B UNLABELLED
Apraxia of Speech
Mayo ClinicSmall moleculePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Apraxia of Speech cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLORTAUCIPIR Mayo Clinic | Phase 4 | BB |
FLUDEOXYGLUCOSE Mayo Clinic | Phase 1 | CC |
ER-176 Mayo Clinic | D |
Same molecule, other indications
PITTSBURGH COMPOUND B UNLABELLED is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →